Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.

Introduction: As ticagrelor, clopidogrel and cangrelor therapies may be used in the same clinical setting, their potential pharmacodynamic interactions are of interest. Hence, we investigated possible interactions between these agents in dogs using a variety of switching protocols.

Methods: Six male dogs all received 7 different dosing regimens separated by 1-5week washout periods: cangrelor (1μg/kg/min, intravenous infusion); ticagrelor (0.

Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor.

Background: Based on in vitro and animal data, PI3Kβ is given an important role in platelet adhesion and aggregation but its role in insulin signaling is unclear.

Objective: To strengthen the PI3Kβ target validation using the novel, short-acting inhibitor AZD6482.

Methods And Results: AZD6482 is a potent, selective and ATP competitive PI3Kβ inhibitor (IC(50) 0.

A Comparison of the Dynamics and Pharmacokinetics of Ropivacaine 7.5 mg/mL with and without Epinephrine Used for Epidural Anaesthesia in Urological Surgery.

Objective: To investigate the effects of adding a vasoconstrictor to ropivacaine for epidural anaesthesia.

Patients And Methods: This randomised, double-blind study included 44 adults scheduled for urological surgery. Patients received either 20mL ropivacaine 7.

Bioavailability and half-life of decabromodiphenyl ether (BDE-209) in rat.

1. The absorption of the flame retardant decabromodiphenyl ether (BDE-209) has been shown by its detection in human plasma, but reported experimental data on its determined in rat, and qualitative analyses by GC/MS of metabolites in plasma were performed. The relative amount of phenolic metabolites was determined in a rat plasma sample obtained after administration of radiolabelled BDE-209.

The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain.

Background: Neuropathic pain is often severe and resistant to pharmacological treatment. The aims of the present study were to assess the analgesic effect of ketamine and lidocaine and to investigate if measurement of different variables of sensibility could be used to identify responders. We also wanted to study if treatment resulted in changes of sensibility.